BioPharmSignal logoBioPharmSignal

Biotech News

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio (CABA)Cabaletta BioCompany update

CABA (CABA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is caba.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CABACabaletta Bio2026-11-05 12:30 EST

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-11-04 21:01 EST

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BMYBMYBristol-Myers Squibb Company2026-10-25 07:30 EST

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

GRIGRI Bio2026-09-28 13:40 EST

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

INMBINmune Bio2026-09-14 11:00 EST

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

IFRXInflarx NV2026-11-03 12:00 EST

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

ZURAZura Bio2026-10-27 11:30 EST

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

ALECAlector2026-10-07 20:05 EST

Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

SABSSAB Biotherapeutics2026-10-01 12:30 EST

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

View all latest news

Cabaletta Bio

Autoimmune Cell Therapy Company Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease. Rese-cel Rese-cel is a fully human CD19-directed CAR T-cell therapy being studied across myositis, systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris. CARTA...

Recent company news

CABACabaletta Bio2026-11-05 12:30 EST

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-11-04 21:01 EST

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CABACabaletta Bio2026-11-03 13:00 EST

Cabaletta Bio to Participate in Upcoming Investor Conferences

CABACabaletta Bio2026-10-05 20:01 EST

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CABACabaletta Bio2026-09-01 12:00 EST

Cabaletta Bio to Participate in Upcoming Investor Conferences

Stock data

Close
1.28 USD
Market cap
600.04M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States